QuartrQuartr

PharmaEssentia: ROPEG expands across MPNs as 9M 2026 revenue reaches NTD 19.7B

Czytanie zajmuje mniej niż 1 minutę

ROPEG’s PV reach exceeds 50 countries, with ET approvals added across four markets in 2026. Revenue reached NTD 19.7B in 9M 2026, while PMF Phase III enrollment and a broader oncology and immunology pipeline support expansion.

Original document: PharmaEssentia Corp. [6446] Slides Release — Nov. 13 2026

Wyłączenie odpowiedzialności